• PDF / 171,365 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 8 Downloads / 150 Views

DOWNLOAD

REPORT

---

1 S

Fondaparinux-sodium/heparin Heparin-induced thrombocytopenia and off-label use: case report

In a retrospective study of 10 patients, conducted at University Hospital of Hradec Kralove from 2014–2018, a 71-year-old patient [sex not stated] was described, who developed heparin-induced thrombocytopenia during treatment with heparin [unfractionated heparin] flushes in haemodialysis. The patient subsequently received off-label therapy with fondaparinux sodium for heparininduced thrombocytopenia. The patient had a history of acute glomerulonephritis. The patient started receiving treatment with heparin [unfractionated heparin] flushes in haemodialysis. After 9 days, the patient’s platelet levels dropped significantly from 224x109/L to 27x109/L. Diagnosis of heparin-induced thrombocytopenia (HIT) was considered. The patient also developed deep vein thrombosis as a clinical manifestation of HIT. The patient’s treatment with heparin was discontinued. The patient started receiving off-label treatment with fondaparinux sodium [Fondaparinux] at a dose of 2.5mg every other day for HIT. The patient’s platelet count recovered completely within 16 days. Dulicek P, et al. Heparin-induced thrombocytopenia treated with fondaparinux: Single center experience. International Angiology 39: 76-81, No. 1, Feb 2020

803508073

» Editorial comment:

0114-9954/20/1826-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 17 Oct 2020 No. 1826